These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 39389740)

  • 1. Clinical Outcomes of Patients Experiencing Transient Loss of Pulse Pressure During High-Risk PCI with Impella.
    Basir MB; Bentley D; Truesdell AG; Kunkel K; Lemor A; Megaly M; Alqarqaz M; Alaswad K; Khandewal A; Jortberg E; Kalra S; Kaki A; Burkhoff D; Moses JW; Pinto DS; Stone GW; O'Neill WW
    J Card Fail; 2024 Oct; 30(10):1287-1299. PubMed ID: 39389740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impella Versus Non-Impella for Nonemergent High-Risk Percutaneous Coronary Intervention.
    Reddy P; Merdler I; Zhang C; Cellamare M; Ben-Dor I; Bernardo NL; Hashim HD; Satler LF; Rogers T; Waksman R
    Am J Cardiol; 2024 Aug; 225():4-9. PubMed ID: 38871158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiographic Characteristics and Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing Impella-Supported High-Risk Percutaneous Coronary Intervention: Insights From the cVAD PROTECT III Study.
    Bharadwaj AS; Abu-Much A; Maini AS; Zhou Z; Li Y; Batchelor WB; Grines CL; Baron SJ; Redfors B; Lansky AJ; Basir MB; O'Neill WW
    Circ Cardiovasc Interv; 2024 Jul; 17(7):e013503. PubMed ID: 38708609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of left-ventricular end-diastolic pressure as a predictor of periprocedural hemodynamic deterioration in patients undergoing Impella supported high-risk percutaneous coronary interventions.
    Al-Rashid F; Mahabadi AA; Johannsen L; Soldat J; Dykun I; Jánosi RA; Totzeck M; Rassaf T
    Int J Cardiol Heart Vasc; 2020 Feb; 26():100445. PubMed ID: 31799370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes among patients with mitral valve regurgitation undergoing Impella-supported high-risk PCI.
    Abu-Much A; Grines CL; Chen S; Batchelor WB; Zhao D; Falah B; Maini AS; Redfors B; Bellumkonda L; Bharadwaj AS; Moses JW; Truesdell AG; Zhang Y; Zhou Z; Baron SJ; Lansky AJ; Basir MB; O'Neill WW; Cohen DJ
    Int J Cardiol; 2024 Dec; 417():132555. PubMed ID: 39270940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and Clinical Correlates of Extended Mechanical Support in Patients Undergoing High-Risk Percutaneous Coronary Intervention in Current Clinical Practice: Insights from the cVAD Registry.
    Davila CD; Sharma S; Krishnamoorthy P; Rengifo-Moreno P; Palacios IF; O'Neill W; Kapur NK; Witzke CF
    Cardiovasc Revasc Med; 2020 Mar; 21(3):342-347. PubMed ID: 31227392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and outcomes of patients requiring prolonged mechanical circulatory support after high-risk percutaneous coronary intervention.
    Min S; Basir MB; Lemor A; Zhou Z; Abu-Much A; Redfors B; Thompson JB; Truesdell AG; Bharadwaj AS; Li Y; Kaki A; Brott BC; Wohns DH; Meraj PM; Daggubati R; Grines CL; O'Neill WW; Moses JW
    EuroIntervention; 2024 Jan; 20(2):e135-e145. PubMed ID: 38224254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-risk percutaneous coronary intervention with the TandemHeart and Impella devices: a single-center experience.
    Schwartz BG; Ludeman DJ; Mayeda GS; Kloner RA; Economides C; Burstein S
    J Invasive Cardiol; 2011 Oct; 23(10):417-24. PubMed ID: 21972160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impella support and acute kidney injury during high-risk percutaneous coronary intervention: The Global cVAD Renal Protection Study.
    Flaherty MP; Moses JW; Westenfeld R; Palacios I; O'Neill WW; Schreiber TL; Lim MJ; Kaki A; Ghiu I; Mehran R
    Catheter Cardiovasc Interv; 2020 May; 95(6):1111-1121. PubMed ID: 31355987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structured Weaning From the Impella Left Ventricular Micro-Axial Pump in Acute Myocardial Infarction With Cardiogenic Shock and Protected Percutaneous Coronary Intervention: Experience From a Non-Cardiac Surgical Centre.
    Slack RJ; McGain F; Cox N; French C; Cheng V; Stub D; Zakhem B; Dade F; Bloom JE; Chan W; Yang Y
    Heart Lung Circ; 2024 Apr; 33(4):460-469. PubMed ID: 38388259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percutaneous Ventricular Assist Devices: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2017; 17(2):1-97. PubMed ID: 28232854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of a pulsatile and a continuous flow left ventricular assist device in high-risk PCI.
    Samol A; Wiemer M; Kaese S
    Int J Cardiol; 2022 Aug; 360():7-12. PubMed ID: 35597491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Impella-supported high-risk nonemergent percutaneous coronary intervention in a large single-center registry.
    Azzalini L; Johal GS; Baber U; Bander J; Moreno PR; Bazi L; Kapur V; Barman N; Kini AS; Sharma SK
    Catheter Cardiovasc Interv; 2021 Jan; 97(1):E26-E33. PubMed ID: 32333721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (The PROTECT I Trial): initial U.S. experience.
    Dixon SR; Henriques JP; Mauri L; Sjauw K; Civitello A; Kar B; Loyalka P; Resnic FS; Teirstein P; Makkar R; Palacios IF; Collins M; Moses J; Benali K; O'Neill WW
    JACC Cardiovasc Interv; 2009 Feb; 2(2):91-6. PubMed ID: 19463408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender disparities with the use of percutaneous left ventricular assist device in patients undergoing percutaneous coronary intervention complicated by cardiogenic shock: From pVAD Working Group.
    Doshi R; Patel K; Decter D; Jauhar R; Meraj P
    Indian Heart J; 2018 Jul; 70 Suppl 1(Suppl 1):S90-S95. PubMed ID: 30122245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Right Ventricular Dysfunction in Patients Undergoing High-Risk PCI with Impella.
    Rommel KP; Bonnet G; Bellumkonda L; Lansky AJ; Zhao D; Thompson JB; Zhang Y; Redfors B; Lurz PC; Granada JF; Bharadwaj AS; Basir MB; O'Neill WW; Burkhoff D
    J Card Fail; 2024 Oct; 30(10):1244-1254. PubMed ID: 39389734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complex High-Risk Indicated Percutaneous Coronary Intervention With Prophylactic Use of the Impella CP Ventricular Assist Device.
    van den Buijs DMF; van den Brink FS; Wilgenhof A; Zivelonghi C; Verouden N; Knaapen P; Sjauw KD; Vermeersch P; Nap A
    J Invasive Cardiol; 2022 Sep; 34(9):E665-E671. PubMed ID: 36001456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Pre-Procedural Blood Pressure on Long-Term Outcomes Following Percutaneous Coronary Intervention.
    Warren J; Nanayakkara S; Andrianopoulos N; Brennan A; Dinh D; Yudi M; Clark D; Ajani AE; Reid CM; Selkrig L; Shaw J; Hiew C; Freeman M; Kaye D; Kingwell BA; Dart AM; Duffy SJ;
    J Am Coll Cardiol; 2019 Jun; 73(22):2846-2855. PubMed ID: 31171090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex-related difference in the use of percutaneous left ventricular assist device in patients undergoing complex high-risk percutaneous coronary intervention: Insight from the cVAD registry.
    Alraies MC; Kaki A; Kajy M; Blank N; Hasan R; Htun WW; Glazier JJ; Elder M; O'Neill WW; Grines CL; Schreiber T
    Catheter Cardiovasc Interv; 2020 Sep; 96(3):536-544. PubMed ID: 31631515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of Impella implantation and outcomes in cardiogenic shock or high-risk percutaneous coronary revascularization.
    Tarantini G; Masiero G; Burzotta F; Pazzanese V; Briguori C; Trani C; Piva T; De Marco F; Di Biasi M; Pagnotta P; Mojoli M; Casu G; Giustino G; Lorenzoni G; Montorfano M; Ancona MB; Pappalardo F; Chieffo A;
    Catheter Cardiovasc Interv; 2021 Aug; 98(2):E222-E234. PubMed ID: 33793051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.